Get the Stockscreener App
52.92
0.04%
0.02
After Hours:
52.92
Soleno Therapeutics Inc stock is traded at $52.92, with a volume of 1.47M.
It is up +0.04% in the last 24 hours and up +34.01% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$52.90
Open:
$52.88
24h Volume:
1.47M
Relative Volume:
0.45
Market Cap:
$2.76B
Revenue:
$190.41M
Net Income/Loss:
$20.48M
P/E Ratio:
237.52
EPS:
0.2228
Net Cash Flow:
$46.66M
1W Performance:
+0.30%
1M Performance:
+34.01%
6M Performance:
+12.91%
1Y Performance:
-30.81%
1-Day Range:
$52.85
$52.92
1-Week Range:
$52.77
$52.92
52-Week Range:
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.92 | 2.76B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine pairs $811M quarter with $2.9B Soleno deal for rare-disease drug - Stock Titan
Neurocrine Biosciences (NBIX) posts strong Q1 2026 results and plans $2.9B Soleno deal - Stock Titan
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Neurocrine in the spotlight: Can growth justify Soleno bet? By Investing.com - Investing.com UK
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - ChartMill
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of - GlobeNewswire
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
SLNO DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Soleno Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar - GlobeNewswire
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline - GlobeNewswire Inc.
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Soleno Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - Scott Coop
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - ChartMill
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Soleno Therapeutics (SLNO) price target decreased by 15.57% to 57.53 - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
Soleno Therapeutics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, ... - Caledonian Record
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - Business Wire
Soleno Therapeutics Executive Compensation, Corporate Governance, and Pay Practices 2025 - Minichart
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Pictet Asset Management Holding SA Has $28.90 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - ChartMill
Neurocrine to acquire Soleno Therapeutics (SLNO) in $53-per-share cash deal - Stock Titan
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ChartMill
SLNO Shareholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Morningstar
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt – Company AnnouncementFT.com - Financial Times
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud - GuruFocus
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Hav - GuruFocus
SOLENO DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
[SC TO-T/A] SOLENO THERAPEUTICS INC Amended Third-Party Tender Offer | SLNO SEC FilingForm SC TO-T/A - Stock Titan
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
MSN - MSN
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):